drugset / Trial / NCT00002767

Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00002767

Phase 3 Unknown 300 enrolled GlaxoSmithKline
RandomizedTreatment

Summary

RATIONALE: Interferon alfa may interfere with the growth of cancer cells.Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether melanoma vaccine plus interferon alfa is more effective than interferon alfa alone in treating patients with metastatic melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without vaccine therapy in treating patients with metastatic melanoma.

Timeline

Start
1996-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Detox-B adjuvant Unknown Subcutaneous
Subject interferon alfa-2b Protein / enzyme biologic Subcutaneous

Indications